Navidea Biopharmaceuticals Inc.
NAVB
NAVB was delisted on the 5th of October, 2023.
79 hedge funds and large institutions have $90.3M invested in Navidea Biopharmaceuticals Inc. in 2013 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 32 increasing their positions, 20 reducing their positions, and 6 closing their positions.
231% more call options, than puts
Call options by funds: $4.87M | Put options by funds: $1.47M
67% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 6
60% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 20
5% more funds holding
Funds holding: 75 → 79 (+4)
4% more capital invested
Capital invested by funds: $87.1M → $90.3M (+$3.18M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Nomura Holdings
Tokyo,
Japan
|
+$4.08M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2M |
| 3 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$1.13M |
| 4 |
PM
Platinum Management
New York
|
+$486K |
| 5 |
State Street
Boston,
Massachusetts
|
+$371K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
-$2.32M |
| 2 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
-$1.25M |
| 3 |
JP Morgan Chase
New York
|
-$649K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$361K |
| 5 |
FAAS
First Allied Advisory Services
San Diego,
California
|
-$182K |
NAVB Hedge Fund Activity: Q3 2013 in Review
79 of the 3,084 institutional investors tracked by Wall St. Rank reported a position in Navidea Biopharmaceuticals Inc. (NAVB) for Q3 2013, worth a combined $90.3M — up 3.7% from $87.1M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new NAVB positions and 6 closed out — a net gain of 4 holders — while 32 added to existing stakes and 20 trimmed.
The largest buyer was Nomura Holdings, adding an estimated $4.08M. The largest seller was Tang Capital Management, exiting entirely with an estimated $2.32M sold.
- 79 institutional investors held Navidea Biopharmaceuticals Inc. (NAVB) as of Q3 2013, up from 75 in Q2 2013.
- Funds reported $90.3M of Navidea Biopharmaceuticals Inc. stock for Q3 2013, up 3.7% quarter-over-quarter.
- 10 funds opened new Navidea Biopharmaceuticals Inc. positions in Q3 2013 and 6 closed out, a net change of +4 holders.
- The largest Navidea Biopharmaceuticals Inc. buyer in Q3 2013 was Nomura Holdings, an estimated $4.08M added.
- The largest Navidea Biopharmaceuticals Inc. seller in Q3 2013 was Tang Capital Management, an estimated $2.32M sold.
Based on aggregated 13F filings for Q3 2013.